EP3122364A4 - Progesterone formulations - Google Patents

Progesterone formulations Download PDF

Info

Publication number
EP3122364A4
EP3122364A4 EP15768772.4A EP15768772A EP3122364A4 EP 3122364 A4 EP3122364 A4 EP 3122364A4 EP 15768772 A EP15768772 A EP 15768772A EP 3122364 A4 EP3122364 A4 EP 3122364A4
Authority
EP
European Patent Office
Prior art keywords
progesterone formulations
progesterone
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15768772.4A
Other languages
German (de)
French (fr)
Other versions
EP3122364A1 (en
Inventor
Janice Cacace
Peter Persicaner
Thorsteinn Thorsteinsson
Frederick Sancilio
Julia Amadio
Brian Bernick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TherapeuticsMD Inc
Original Assignee
TherapeuticsMD Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TherapeuticsMD Inc filed Critical TherapeuticsMD Inc
Publication of EP3122364A1 publication Critical patent/EP3122364A1/en
Publication of EP3122364A4 publication Critical patent/EP3122364A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
EP15768772.4A 2014-03-28 2015-03-27 Progesterone formulations Withdrawn EP3122364A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972068P 2014-03-28 2014-03-28
PCT/US2015/023041 WO2015148952A1 (en) 2014-03-28 2015-03-27 Progesterone formulations

Publications (2)

Publication Number Publication Date
EP3122364A1 EP3122364A1 (en) 2017-02-01
EP3122364A4 true EP3122364A4 (en) 2017-10-25

Family

ID=54196452

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15768772.4A Withdrawn EP3122364A4 (en) 2014-03-28 2015-03-27 Progesterone formulations

Country Status (10)

Country Link
EP (1) EP3122364A4 (en)
JP (2) JP2017509630A (en)
KR (1) KR20160137597A (en)
AR (1) AR099872A1 (en)
AU (1) AU2015237243A1 (en)
CA (1) CA2942568A1 (en)
IL (1) IL247828A0 (en)
MX (1) MX2016011706A (en)
RU (1) RU2016136666A (en)
WO (1) WO2015148952A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210386757A1 (en) * 2018-10-17 2021-12-16 Sarah S. Stadler Methods of Treating Menopausal Symptoms Using Low Dose Progesterone
CN112336699A (en) * 2019-08-09 2021-02-09 南京科宁检测科技有限公司 Progesterone vaginal slow-release soft capsule and its preparation method
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068186A1 (en) * 2002-02-11 2003-08-21 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
WO2003077923A1 (en) * 2002-03-14 2003-09-25 Watson Pharmaceuticals, Inc. Progesterone oral drug delivery system
WO2006128057A2 (en) * 2005-05-26 2006-11-30 Duramed Pharmaceuticals, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
WO2011160136A2 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone containing oral dosage forms and related methods
WO2013022783A2 (en) * 2011-08-05 2013-02-14 Lipocine Inc. Progesterone containing oral dosage forms and related methods
US20130338123A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) * 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2004504342A (en) * 2000-07-24 2004-02-12 ファルマシア・アンド・アップジョン・カンパニー Self-emulsifying drug delivery system for highly water-insoluble lipophilic drugs
US20130338122A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068186A1 (en) * 2002-02-11 2003-08-21 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
WO2003077923A1 (en) * 2002-03-14 2003-09-25 Watson Pharmaceuticals, Inc. Progesterone oral drug delivery system
WO2006128057A2 (en) * 2005-05-26 2006-11-30 Duramed Pharmaceuticals, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
WO2011160136A2 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone containing oral dosage forms and related methods
WO2013022783A2 (en) * 2011-08-05 2013-02-14 Lipocine Inc. Progesterone containing oral dosage forms and related methods
US20130338123A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) * 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015148952A1 *

Also Published As

Publication number Publication date
MX2016011706A (en) 2017-05-01
RU2016136666A3 (en) 2018-11-07
WO2015148952A1 (en) 2015-10-01
KR20160137597A (en) 2016-11-30
RU2016136666A (en) 2018-05-03
JP2017509630A (en) 2017-04-06
AU2015237243A1 (en) 2016-09-29
CA2942568A1 (en) 2015-10-01
IL247828A0 (en) 2016-11-30
AR099872A1 (en) 2016-08-24
JP2019206540A (en) 2019-12-05
EP3122364A1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
EP3102190A4 (en) Novel pharmaceutical formulations
EP3193888A4 (en) Novel formulations
EP3040326A4 (en) Halo-olefin composition
EP3192518A4 (en) Anti-inflammatory agent
EP3186043A4 (en) Produce preparation
EP3132487A4 (en) Electrolyte formulations
EP3096757A4 (en) Apilimod compositions and methods for using same
EP3165200A4 (en) Supporter
EP3067338A4 (en) Water-settable composition
EP3221420A4 (en) Photochromic-electrochromic compositions
EP3191114A4 (en) Occidiofungin formulations and uses thereof
EP3235493A4 (en) Preparation
EP3002061A4 (en) Pulverizer
EP3231430A4 (en) Composition
EP3098298A4 (en) Cell-seeding and -culturing device
EP3191110A4 (en) Polygalacturonan rhamnogalacturonan1 (pgrg1) composition
EP3373928A4 (en) Novel formulations
EP3119392A4 (en) Ocular formulations
EP3125321A4 (en) Organic-semiconductor-film-forming composition
IL247828A0 (en) Progesterone formulations
EP3226882A4 (en) Therapeutic compositions
EP3162799A4 (en) Fluoroalkylating agent
EP3214161A4 (en) Cleaning-agent composition
EP3368013A4 (en) Liquid buprenorphine formulations
EP3088002A4 (en) Extended release formulation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20160919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170922

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/30 20060101ALI20170918BHEP

Ipc: A61K 31/57 20060101AFI20170918BHEP

Ipc: A61K 9/48 20060101ALI20170918BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190906

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200117